SM
RUBY

SG3 Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

SG3 Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,879
Closed -$248K – 1378
2021
Q3 		$248K Buy
+13,879
New +$302K 0.01% 746
2021
Q2 		– Sell
-17,000
Closed -$451K – 1445
2021
Q1 		$451K Buy
+17,000
New +$248K 0.01% 806

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SG3 Management's RUBY Position: Q4 2021 in Review

SG3 Management sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2021, closing a stake of 13,879 shares — an estimated $248K sold.

SG3 Management first reported a position in RUBY in Q1 2021 and held it in 2 quarters. The position peaked at $451K in Q1 2021. 108 funds tracked by Wall St. Rank hold RUBY as of Q4 2021.

  • SG3 Management reported no remaining Rubius Therapeutics, Inc position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 13,879 Rubius Therapeutics, Inc shares in Q4 2021, an estimated $248K.
  • SG3 Management first reported a position in Rubius Therapeutics, Inc in Q1 2021 and held it in 2 quarters.
  • SG3 Management's Rubius Therapeutics, Inc position peaked at $451K in Q1 2021.
  • 108 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.